BioCentury
ARTICLE | Clinical News

Azilect rasagiline regulatory update

June 30, 2014 7:00 AM UTC

FDA approved an sNDA for Azilect rasagiline to include use as an adjunct to dopamine agonists to treat Parkinson’s disease. The irreversible selective inhibitor of monoamine oxidase B (MAO-B) is alre...